Elektrofi, a Boston-based biotechnology company focused on drug formulation and delivery innovations, has entered into a collaboration and license agreement with argenx to explore new subcutaneous formulations for therapeutic products directed at the human neonatal Fc receptor (FcRn), including efgartigimod, and up to one additional target.

The Elektrofi-enabled formulations are aimed to promote additional optionality for patients through at-home and self-administration capabilities.
 
Under the terms of the agreement, argenx will make an upfront payment and future milestones payments across both targets pending achievement of pre-defined development, regulatory, and commercial milestones. Elektrofi will also receive a mid-single digit royalty on sales of commercialized products.
 
“Our agreement with argenx is another strong indicator of industry interest in our technology, the benefit of at-home and self-administration options, and our universal commitment to optimizing the patient experience,” said Chase Coffman, co-founder and CEO, Elektrofi. “We are excited to be working closely with the argenx team to develop product candidates that may address severe and debilitating diseases.”